UBS Group’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-6,604
| Closed | -$4K | – | 8813 |
|
|
2019
Q3 | $4K | Buy |
6,604
+6,561
| +15,258% | +$3.65K | ﹤0.01% | 7603 |
|
|
2019
Q2 | $0 | Sell |
43
-9,543
| -100% | -$6.85K | ﹤0.01% | 8516 |
|
|
2019
Q1 | $11K | Buy |
9,586
+9,543
| +22,193% | +$9.33K | ﹤0.01% | 6792 |
|
|
2018
Q4 | $0 | Sell |
43
-3,045
| -99% | -$2.78K | ﹤0.01% | 8707 |
|
|
2018
Q3 | $5K | Buy |
3,088
+1,989
| +181% | +$2.64K | ﹤0.01% | 7541 |
|
|
2018
Q2 | $0 | Sell |
1,099
-8,087
| -88% | -$2.43K | ﹤0.01% | 8634 |
|
|
2018
Q1 | $3K | Buy |
9,186
+1,036
| +13% | +$679 | ﹤0.01% | 7500 |
|
|
2017
Q4 | $8K | Buy |
8,150
+7,032
| +629% | +$8.08K | ﹤0.01% | 7200 |
|
|
2017
Q3 | $2K | Sell |
1,118
-7,338
| -87% | -$8.97K | ﹤0.01% | 7538 |
|
|
2017
Q2 | $10K | Buy |
8,456
+5,104
| +152% | +$5.85K | ﹤0.01% | 6818 |
|
|
2017
Q1 | $4K | Sell |
3,352
-17,792
| -84% | -$19.5K | ﹤0.01% | 7141 |
|
|
2016
Q4 | $21K | Buy |
21,144
+20,686
| +4,517% | +$23.2K | ﹤0.01% | 6500 |
|
|
2016
Q3 | $0 | Buy |
458
+415
| +965% | +$501 | ﹤0.01% | 8358 |
|
|
2016
Q2 | $0 | Hold |
43
| – | – | ﹤0.01% | 8377 |
|
|
2016
Q1 | $0 | Hold |
43
| – | – | ﹤0.01% | 8826 |
|
|
2015
Q4 | $0 | Hold |
43
| – | – | ﹤0.01% | 8962 |
|
|
2015
Q3 | $0 | Sell |
43
-1,711
| -98% | -$3.3K | ﹤0.01% | 9086 |
|
|
2015
Q2 | $4K | Sell |
1,754
-2,812
| -62% | -$7.2K | ﹤0.01% | 8036 |
|
|
2015
Q1 | $14K | Buy |
4,566
+4,560
| +76,000% | +$14.4K | ﹤0.01% | 7404 |
|
|
2014
Q4 | $0 | Buy |
+6
| New | +$20 | ﹤0.01% | 9729 |
|
UBS Group's CELGZ Position: Q4 2019 in Review
UBS Group sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2019, closing a stake of 6,604 shares — an estimated $4K sold.
UBS Group first reported a position in CELGZ in Q4 2014 and held it in 20 quarters. The position peaked at $21K in Q4 2016. 0 funds tracked by Wall St. Rank hold CELGZ as of Q4 2019.
- UBS Group reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
- UBS Group sold 6,604 Celgene Corporation Contingent Value Rights shares in Q4 2019, an estimated $4K.
- UBS Group first reported a position in Celgene Corporation Contingent Value Rights in Q4 2014 and held it in 20 quarters.
- UBS Group's Celgene Corporation Contingent Value Rights position peaked at $21K in Q4 2016.
- 0 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2019.
Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.